Speaker illustration

Mrs Amiee Kang

Bristol Myers Squibb, Princeton (United States of America)

Real-world assessment of antiplatelet treatment therapies for acute coronary syndrome (ACS) patients in the United States in a nationwide Electronic Health Record in 2018-2020

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: Real-world evidence in acute coronary syndromes (1)


Real-world assessment of anti-platelet therapies for recurrent stroke prevention in non-atrial fibrillation Japanese patients after recent ischemic stroke or transient ischemic attack

Event: ESC Congress 2022

Topic: Cardiovascular Pharmacotherapy

Session: Short and long-term antiplatelet therapy in clinical practice


Time at home among nonvalvular atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants versus warfarin

Event: ESC Congress 2021 - The Digital Experience

Topic: Oral Anticoagulation

Session: Atrial fibrillation e-posters


Comparative effectiveness and safety of non-VKA oral anticoagulants versus warfarin in non-valvular atrial fibrillation patients with differential treatment duration: an ARISTOPHANES study analysis

Event: ESC Congress 2019

Topic: Oral Anticoagulation

Session: Atrial fibrillation and oral anticoagulation 6


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb